FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206070771> ?p ?o ?g. }

• W3206070771 endingPage "1455" @default.
• W3206070771 startingPage "1455" @default.
• W3206070771 abstract "Background Myeloid dysfunction is an emerging hallmark of microenvironment changes occurring in multiple myeloma (MM). Our previous work showed that FcγRI/CD64 overexpression in neutrophils of newly diagnosed MM patients is associated to inferior outcomes, reduced oxidative bursts and phagocytosis, with an increased risk of bacterial infections. Pomalidomide is a novel immune-modulatory drug approved for relapsed/refractory patients (RRMM), with drug-related neutropenia as major limitation to treatment. Patients and methods Herein, we describe a prospective analysis of 51 consecutive RRMM patients treated with pomalidomide and dexamethasone (PomDex) from March 2015 through December 2016, associated with secondary prophylaxis with filgrastim (G-CSF) in case of neutrophil count <1500 cells/μL. Neutrophil function was investigated by flow cytometry, including the phagocytosis, oxidative bursts, and median fluorescence intensity of FcγRI-CD64. Controls included a group of newly diagnosed symptomatic MM (NDMM), asymptomatic (smoldering myeloma, MGUS) and healthy subjects referred to our Center in the same time-frame. Results Compared to controls, RRMM neutrophils had higher expression of FcγRI/CD64 and lower phagocytic activity and oxidative bursts. We maintained median leukocyte counts higher than 3.5 × 109/L for 6 cycles, and median neutrophil counts higher than 1.5 × 109/L, with only 6 (11%) patients developing grade 3-4 infections, without pomalidomide dose reduction. After 4 cycles of PomDex, FcγRI/CD64 was further increased in neutrophils, and phagocytic activity and oxidative bursts recovered independently from filgrastim exposure and the quality of hematological responses. Similarly, in NDMM patients, lenalidomide but not bortezomib upregulated FcγRI/CD64 expression, improving phagocytic activity and oxidative bursta as tested in vitro. Conclusions Our combined biological and clinical data provide new information on the ability of pomalidomide and lenalidomide to modulate the functional activity of neutrophils, despite their chronic activation due to FcγRI/CD64 overexpression." @default.
• W3206070771 created "2021-10-25" @default.
• W3206070771 creator A5000098294 @default.
• W3206070771 creator A5003679742 @default.
• W3206070771 creator A5010686749 @default.
• W3206070771 creator A5018769545 @default.
• W3206070771 creator A5034393745 @default.
• W3206070771 creator A5040930723 @default.
• W3206070771 creator A5062195312 @default.
• W3206070771 creator A5065852754 @default.
• W3206070771 date "2021-10-13" @default.
• W3206070771 modified "2023-09-23" @default.
• W3206070771 title "Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils" @default.
• W3206070771 cites W1538460158 @default.
• W3206070771 cites W1991656907 @default.
• W3206070771 cites W2000047150 @default.
• W3206070771 cites W2036942759 @default.
• W3206070771 cites W2046280953 @default.
• W3206070771 cites W2073040868 @default.
• W3206070771 cites W2081483716 @default.
• W3206070771 cites W2090630520 @default.
• W3206070771 cites W2091773528 @default.
• W3206070771 cites W2098012996 @default.
• W3206070771 cites W2124129446 @default.
• W3206070771 cites W2136541422 @default.
• W3206070771 cites W2148323116 @default.
• W3206070771 cites W2174938993 @default.
• W3206070771 cites W2178963310 @default.
• W3206070771 cites W2295129153 @default.
• W3206070771 cites W2394652810 @default.
• W3206070771 cites W2580984508 @default.
• W3206070771 cites W2614781853 @default.
• W3206070771 cites W2745217803 @default.
• W3206070771 cites W2779357669 @default.
• W3206070771 cites W2790994467 @default.
• W3206070771 cites W2790998617 @default.
• W3206070771 cites W2792859185 @default.
• W3206070771 cites W2801059496 @default.
• W3206070771 cites W2806380367 @default.
• W3206070771 cites W2806713515 @default.
• W3206070771 cites W2914351801 @default.
• W3206070771 cites W2963314346 @default.
• W3206070771 cites W2966314303 @default.
• W3206070771 cites W2980778150 @default.
• W3206070771 cites W3004739256 @default.
• W3206070771 cites W3018331841 @default.
• W3206070771 cites W3019972849 @default.
• W3206070771 cites W3022273008 @default.
• W3206070771 cites W3030876625 @default.
• W3206070771 doi "https://doi.org/10.3390/biomedicines9101455" @default.
• W3206070771 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8533128" @default.
• W3206070771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34680570" @default.
• W3206070771 hasPublicationYear "2021" @default.
• W3206070771 type Work @default.
• W3206070771 sameAs 3206070771 @default.
• W3206070771 citedByCount "2" @default.
• W3206070771 countsByYear W32060707712022 @default.
• W3206070771 crossrefType "journal-article" @default.
• W3206070771 hasAuthorship W3206070771A5000098294 @default.
• W3206070771 hasAuthorship W3206070771A5003679742 @default.
• W3206070771 hasAuthorship W3206070771A5010686749 @default.
• W3206070771 hasAuthorship W3206070771A5018769545 @default.
• W3206070771 hasAuthorship W3206070771A5034393745 @default.
• W3206070771 hasAuthorship W3206070771A5040930723 @default.
• W3206070771 hasAuthorship W3206070771A5062195312 @default.
• W3206070771 hasAuthorship W3206070771A5065852754 @default.
• W3206070771 hasBestOaLocation W32060707711 @default.
• W3206070771 hasConcept C126322002 @default.
• W3206070771 hasConcept C203014093 @default.
• W3206070771 hasConcept C2776063141 @default.
• W3206070771 hasConcept C2776364478 @default.
• W3206070771 hasConcept C2776447464 @default.
• W3206070771 hasConcept C2776694085 @default.
• W3206070771 hasConcept C2777063308 @default.
• W3206070771 hasConcept C2777432695 @default.
• W3206070771 hasConcept C2777478702 @default.
• W3206070771 hasConcept C2778461978 @default.
• W3206070771 hasConcept C2778524551 @default.
• W3206070771 hasConcept C2778850193 @default.
• W3206070771 hasConcept C553184892 @default.
• W3206070771 hasConcept C71924100 @default.
• W3206070771 hasConcept C90924648 @default.
• W3206070771 hasConceptScore W3206070771C126322002 @default.
• W3206070771 hasConceptScore W3206070771C203014093 @default.
• W3206070771 hasConceptScore W3206070771C2776063141 @default.
• W3206070771 hasConceptScore W3206070771C2776364478 @default.
• W3206070771 hasConceptScore W3206070771C2776447464 @default.
• W3206070771 hasConceptScore W3206070771C2776694085 @default.
• W3206070771 hasConceptScore W3206070771C2777063308 @default.
• W3206070771 hasConceptScore W3206070771C2777432695 @default.
• W3206070771 hasConceptScore W3206070771C2777478702 @default.
• W3206070771 hasConceptScore W3206070771C2778461978 @default.
• W3206070771 hasConceptScore W3206070771C2778524551 @default.
• W3206070771 hasConceptScore W3206070771C2778850193 @default.
• W3206070771 hasConceptScore W3206070771C553184892 @default.
• W3206070771 hasConceptScore W3206070771C71924100 @default.
• W3206070771 hasConceptScore W3206070771C90924648 @default.
• W3206070771 hasFunder F4320307607 @default.

• next